Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.

Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST.

J Cell Physiol. 2019 Feb 15. doi: 10.1002/jcp.28294. [Epub ahead of print]

PMID:
30770553
2.

Acute Lymphoblastic Leukemia in the Older Adult.

Aldoss I, Forman SJ, Pullarkat V.

J Oncol Pract. 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271.

PMID:
30763199
3.

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Forman SJ, Marcucci G, Pullarkat V.

J Cell Physiol. 2019 Jan 8. doi: 10.1002/jcp.28091. [Epub ahead of print]

PMID:
30623427
4.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D.

Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.

5.

Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.

Mei M, Aldoss I, Marcucci G, Pullarkat V.

Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13.

PMID:
30499168
6.

Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?

Aldoss I, Pullarkat V.

Bone Marrow Transplant. 2019 Jan;54(1):3-5. doi: 10.1038/s41409-018-0398-8. Epub 2018 Nov 16. No abstract available.

PMID:
30446742
7.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A.

Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.

8.

Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.

Chen J, Ngo D, Aldoss I, Shayani S, Tsai NC, Pullarkat V.

Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1519811. [Epub ahead of print]

PMID:
30322332
9.

Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.

Aldoss I, Kamal MO, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2019 Feb;25(2):e41-e45. doi: 10.1016/j.bbmt.2018.09.041. Epub 2018 Oct 5.

PMID:
30292743
10.

The emerging story of acute lymphoblastic leukemia among the Latin American population - biological and clinical implications.

Quiroz E, Aldoss I, Pullarkat V, Rego E, Marcucci G, Douer D.

Blood Rev. 2019 Jan;33:98-105. doi: 10.1016/j.blre.2018.08.002. Epub 2018 Aug 14. Review.

PMID:
30126753
11.

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G.

Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16.

12.

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.

Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H, Spielberger R, O'Donnell M, Snyder D, Slavin T, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Oct;103(10):1662-1668. doi: 10.3324/haematol.2018.193599. Epub 2018 Jun 14.

13.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15. No abstract available.

14.

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.

Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.

Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.

15.

Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.

Burke PW, Aldoss I, Lunning MA, Devlin SM, Tallman MS, Pullarkat V, Mohrbacher AM, Douer D.

Leuk Res. 2018 Mar;66:49-56. doi: 10.1016/j.leukres.2017.12.013. Epub 2018 Jan 3.

PMID:
29407583
16.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25.

PMID:
29197676
17.

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.

Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, Hong H, Padeganeh A, Bedell V, Cao T, Khaled SK, Malki MMA, Salhotra A, Ali H, Aribi A, Palmer J, Aoun P, Spielberger R, Stein AS, Snyder D, O'Donnell MR, Murata-Collins J, Senitzer D, Weisenburger D, Forman SJ, Pullarkat V, Marcucci G, Pillai R, Nakamura R.

Haematologica. 2017 Dec;102(12):2030-2038. doi: 10.3324/haematol.2017.172544. Epub 2017 Sep 29.

18.

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome.

Piatek CI, Vergara-Lluri ME, Pullarkat V, Siddiqi IN, O'Connell C, Brynes RK, Feinstein DI.

Acta Haematol. 2017;138(3):129-137. doi: 10.1159/000479103. Epub 2017 Sep 2.

PMID:
28866671
19.

Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.

Kumar B, Garcia M, Weng L, Jung X, Murakami JL, Hu X, McDonald T, Lin A, Kumar AR, DiGiusto DL, Stein AS, Pullarkat VA, Hui SK, Carlesso N, Kuo YH, Bhatia R, Marcucci G, Chen CC.

Leukemia. 2018 Mar;32(3):575-587. doi: 10.1038/leu.2017.259. Epub 2017 Aug 17.

20.

Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.

Zeidan AM, Pullarkat VA, Komrokji RS.

Crit Rev Oncol Hematol. 2017 Sep;117:57-66. doi: 10.1016/j.critrevonc.2017.07.002. Epub 2017 Jul 12. Review.

PMID:
28807236
21.

Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.

Kumar B, Kalvala A, Chu S, Rosen S, Forman SJ, Marcucci G, Chen CC, Pullarkat V.

Leuk Res. 2017 Aug;59:124-135. doi: 10.1016/j.leukres.2017.05.007. Epub 2017 May 10.

PMID:
28646646
22.

Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.

Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O'Donnell M, Stein AS, Marcucci G, Forman S, Pullarkat V.

Am J Hematol. 2017 Sep;92(9):858-865. doi: 10.1002/ajh.24783. Epub 2017 Jun 5.

23.

Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.

Hamilton BK, Rybicki L, Abounader D, Adekola K, Advani A, Aldoss I, Bachanova V, Bashey A, Brown S, DeLima M, Devine S, Flowers CR, Ganguly S, Jagasia M, Kennedy VE, Kim DDH, McGuirk J, Pullarkat V, Romee R, Sandhu K, Smith M, Ueda M, Viswabandya A, Vu K, Wall S, Zeichner SB, Perales MA, Majhail NS.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1117-1121. doi: 10.1016/j.bbmt.2017.04.003. Epub 2017 Apr 7.

24.

Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.

Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J.

Biol Blood Marrow Transplant. 2017 Apr;23(4):618-624. doi: 10.1016/j.bbmt.2017.01.067. Epub 2017 Jan 10.

25.

Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children.

Aldoss IT, Marcucci G, Pullarkat V.

Oncology (Williston Park). 2016 Dec 15;30(12):1080-91. Review.

26.

Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.

Aldoss I, Stiller T, Song J, Al Malki M, Ali H, Salhotra A, Aribi A, Khaled S, Gaytan P, Murata-Collins J, Palmer J, Snyder D, O'Donnell M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Am J Hematol. 2017 Feb;92(2):E18-E19. doi: 10.1002/ajh.24604. No abstract available.

27.
28.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia.

Al Malki MM, Aldoss I, Stiller T, Nakamura R, Snyder DS, Forman SJ, Pullarkat V.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):519-522. doi: 10.1016/j.clml.2016.06.005. Epub 2016 Jun 8.

PMID:
27394652
29.

Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Aldoss I, Gaal K, Al Malki MM, Ali H, Nakamura R, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1900-1903. doi: 10.1016/j.bbmt.2016.06.022. Epub 2016 Jun 23.

30.

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-1356. doi: 10.1016/j.bbmt.2016.04.018. Epub 2016 Apr 27. No abstract available.

31.

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Aldoss I, Tsai NC, Slovak ML, Palmer J, Alvarnas J, Marcucci G, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1212-1217. doi: 10.1016/j.bbmt.2016.03.025. Epub 2016 Apr 1.

32.

Treatment of the older adult with ALL: An urgent call to action.

Pullarkat V.

Leuk Res. 2016 Feb;41:3-4. doi: 10.1016/j.leukres.2016.01.003. Epub 2016 Jan 14. No abstract available.

PMID:
26818571
33.

Improving erythropoiesis: a compelling case for iron chelation in myelofibrosis.

Pullarkat V.

Eur J Haematol. 2016 Jun;96(6):549-50. doi: 10.1111/ejh.12702. No abstract available.

PMID:
26572646
34.

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia.

Aldoss I, Al Malki MM, Stiller T, Cao T, Sanchez JF, Palmer J, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2016 Mar;22(3):575-8. doi: 10.1016/j.bbmt.2015.10.016. Epub 2015 Oct 19.

35.

Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.

Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V.

Eur J Haematol. 2016 Apr;96(4):375-80. doi: 10.1111/ejh.12600. Epub 2015 Jun 25.

PMID:
26095294
36.

Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease.

Gonsalves CS, Li C, Mpollo MS, Pullarkat V, Malik P, Tahara SM, Kalra VK.

Biochem J. 2015 Jun 15;468(3):409-23. doi: 10.1042/BJ20141138. Epub 2015 Apr 16.

37.

Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Aldoss I, Stiller T, Cao TM, Palmer JM, Thomas SH, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1326-9. doi: 10.1016/j.bbmt.2015.03.021. Epub 2015 Apr 1.

38.

Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome.

Aldoss I, Dagis A, Palmer J, Forman S, Pullarkat V.

Bone Marrow Transplant. 2015 May;50(5):746-8. doi: 10.1038/bmt.2015.8. Epub 2015 Mar 2. No abstract available.

PMID:
25730188
39.

Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.

Pullarkat V, Aldoss I.

Crit Rev Oncol Hematol. 2015 Jul;95(1):38-45. doi: 10.1016/j.critrevonc.2015.01.005. Epub 2015 Jan 15. Review.

PMID:
25624175
40.

Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature.

Vergara-Lluri ME, Piatek CI, Pullarkat V, Siddiqi IN, O'Connell C, Feinstein DI, Brynes RK.

Hum Pathol. 2014 Nov;45(11):2183-91. doi: 10.1016/j.humpath.2014.07.017. Epub 2014 Aug 13. Review.

PMID:
25282037
41.

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P.

J Clin Oncol. 2014 Oct 10;32(29):3264-74. doi: 10.1200/JCO.2014.55.2018. Epub 2014 Aug 25.

42.

Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation.

Dadwal SS, Tegtmeier B, Liu X, Frankel P, Ito J, Forman SJ, Pullarkat V.

Eur J Haematol. 2015 Mar;94(3):235-42. doi: 10.1111/ejh.12421. Epub 2014 Sep 13.

PMID:
25082161
43.

Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.

Selleslag D, Bird R, Altomare I, Giagounidis A, Janssens A, Pabinger I, Pullarkat V, Wei H, Kreuzbauer G.

Eur J Haematol. 2015 Feb;94(2):169-76. doi: 10.1111/ejh.12415. Epub 2014 Aug 8.

PMID:
25039799
44.

Iron chelators induce autophagic cell death in multiple myeloma cells.

Pullarkat V, Meng Z, Donohue C, Yamamoto VN, Tomassetti S, Bhatia R, Krishnan A, Forman SJ, Synold TW.

Leuk Res. 2014 Aug;38(8):988-96. doi: 10.1016/j.leukres.2014.06.005. Epub 2014 Jun 17.

PMID:
24998390
45.

A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.

Senthil M, Chaudhary P, Smith DD, Ventura PE, Frankel PH, Pullarkat V, Trisal V.

Thromb Res. 2014 Jul;134(1):165-8. doi: 10.1016/j.thromres.2014.04.022. Epub 2014 Apr 29.

PMID:
24830901
46.

Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.

Pullarkat V, Meng Z, Tahara SM, Johnson CS, Kalra VK.

Hemoglobin. 2014;38(3):188-95. doi: 10.3109/03630269.2014.898651. Epub 2014 Mar 26.

PMID:
24670032
47.

Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.

Douer D, Aldoss I, Lunning MA, Burke PW, Ramezani L, Mark L, Vrona J, Park JH, Tallman MS, Avramis VI, Pullarkat V, Mohrbacher AM.

J Clin Oncol. 2014 Mar 20;32(9):905-11. doi: 10.1200/JCO.2013.50.2708. Epub 2014 Feb 10.

PMID:
24516026
48.

Nodular regenerative hyperplasia causing portal hypertension in a patient with chronic graft versus host disease: response to sirolimus.

Choe H, Aldoss I, Chaudhary P, Donovan J, Petrovic L, Pullarkat V.

Acta Haematol. 2014;132(1):49-52. doi: 10.1159/000356736. Epub 2014 Jan 15. Review. No abstract available.

PMID:
24434665
49.

Iron toxicity in hematopoietic stem cell transplantation: Strike while the iron is labile.

Pullarkat V.

Acta Haematol. 2014;131(4):220-1. doi: 10.1159/000355827. Epub 2013 Dec 3. No abstract available.

PMID:
24335205
50.

The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.

Aldoss I, Ji L, Haider M, Pullarkat V.

Acta Haematol. 2014;131(4):202-7. doi: 10.1159/000354820. Epub 2013 Nov 27.

PMID:
24296475

Supplemental Content

Loading ...
Support Center